

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Date Submitted: June 13, 2007

(use as many sheets as necessary)

Sheet

1

of

5

Complete if Known

Application Number

10/804,576

Filing Date

03/19/2004

First Named Inventor

Fred H. MILLER

Art Unit

1609

Examiner Name

Aradhana Sasan

Attorney Docket Number

027668-0108

NOV 19 2007

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1	3,072,528	01-08-1963	KLUDAH et al.		
A2	4,578,075	03-25-1986	URQUHART et al.		
A3	4,606,909	08-19-1986	BECHGAARD et al.		
A4	4,627,808	12-09-1986	HUGHES		
A5	4,642,233	02-10-1987	URQUHART et al.		
A6	4,681,583	07-21-1987	URQUHART et al.		
A7	4,695,466	09-22-1987	MORISHITA et al.		
A8	4,764,359	08-16-1988	LEMELSON		
A9	4,702,732	10-27-1987	POWERS et al.		
A10	4,773,907	09-27-1988	URQUHART et al.		
A11	4,793,493	12-27-1988	MAKIEJ		
A12	4,822,619	04-18-1989	EICHEL et al.		
A13	4,863,741	09-05-1989	BECKER		
A14	4,904,476	02-27-1990	MEHTA et al.		
A15	4,936,461	06-26-1990	MAKIEJ		
A16	4,994,279	02-19-1991	AOKI et al.		
A17	5,017,379	05-21-1991	LEMELSON		
A18	5,196,205	03-23-1993	BORODY		
A19	5,256,684	10-26-1993	MARSHALL		
A20	5,310,555	05-10-1994	ZIMMER		
A21	5,314,696	05-24-1994	PAULOS		
A22	5,394,980	03-07-1995	TSAI		
A23	5,472,695	12-05-1995	NEEMAN et al.		
A24	5,472,708	12-05-1995	CHEN		
A25	5,501,857	03-26-1996	ZIMMER		
A26	5,558,878	09-24-1996	PAULOS		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov under "Intellectual Property Basics" and "Patent Information" and Standard ST.1.3. The Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the use of symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: June 13, 2007

(use as many sheets as necessary)

Sheet 2 of 5

Complete If Known

Application Number	10/604,576
Filing Date	03/19/2004
First Named Inventor	Fred H. MILLER
Art Unit	1609
Examiner Name	Aradhana Sasan
Attorney Docket Number	027668-0108

U.S. PATENT DOCUMENTS

	Document Number		
A27	5,560,912	10-01-1996	NEEMAN et al.
A28	5,562,918	10-08-1996	STIMPSON
A29	5,576,019	11-19-1996	PAULOS
A30	5,582,837	12-10-1996	SHELL
A31	5,587,837	12-24-1996	KEBO
A32	5,672,359	09-30-1997	DIGENIS et al.
A33	5,674,858	10-07-1997	McCOLM
A34	6,024,980	02-15-2000	HOY
A35	6,262,092	07-17-2001	CHANG et al.
A36	6,350,468 B1	02-26-2002	SANSO
A37	6,352,719	03-05-2002	BROWN et al.
A38	6,455,574	09-24-2002	BUCH
A39	6,486,182	11-26-2002	CHANG et al.
A40	6,517,866 B1	02-11-2003	AM ENDE et al.
A41	6,569,152 B2	05-27-2003	BRINES et al.
A42	6,620,806	09-16-2003	DAY et al.
A43	6,737,145	05-18-2004	WATANABE et al.
A44	US 2002/0081333 A1	06-27-2002	OSHLACK et al.
A45	US 2002/0094992 A1	07-18-2002	MacLEAN
A46	US 2002/0192277 A1	12-19-2002	OSHLACK et al.
A47	US 2003/0035839 A1	02-20-2003	HIRSH et al.
A48	US 2003/0068369 A1	04-10-2003	McALLISTER et al.
A49	US 2003/0194428 A1	10-16-2003	MILLER et al.
A50	US 2003/0194429 A1	10-16-2003	MILLER et al.
A51	US 2003/0194430 A1	10-16-2003	MILLER et al.
A52	US 2003/0194431 A1	10-16-2003	MILLER et al.
A53	US 2005/0008690 A1	01-13-2005	MILLER

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds of USPTO Patent Documents at www.uspto.gov/ptabuspatentinfo/3.htm. Enter citation designation number if the reference is a USPTO patent document. 3 Enter citation designation number if the reference is a non-USPTO patent document. 4 Enter citation designation number if the reference is a non-USPTO patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (or by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: June 13, 2007

(use as many sheets as necessary)

Sheet

3

of

5

Complete if Known

Application Number	10/804,576
Filing Date	03/19/2004
First Named Inventor	Fred H. MILLER
Art Unit	1609
Examiner Name	Aradhana Sasan
Attorney Docket Number	027668-0108

U.S. PATENT DOCUMENTS

	Document Number			
A54	5 074 426	12-24-1991	Goodhart et al.	
A55	5 674 530	10-07-1997	AMIDON et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	A56	DE 27 29 068 A1	01-11-1979	Liedtke		
	A57	EP 0141373 A2	05-15-1985	Plant Genetics, Inc.		
	A58	EP 0228067 A2	07-08-1987	Taisho Pharmaceutical Co.		
	A59	EP 0284017 A1	09-28-1988	Zambon Group S.p.A.		
	A60	EP 0319318 A2	06-07-1989	McNeil Consumer Products Company		
	A61	EP 0325571 A1	07-26-1989	KabiVitrum AB		
	A62	FR 1454013	09-30-1966	PLURIPHARM		
	A63	FR 2524311	04-05-1982	Azalbert Gilles		
	A64	GB 2103564 A	02-23-1983	Canadian Minister of National Defence		
	A65	GB 2365336 A	02-20-2002	MW Encap Limited		
	A66	JP 60-193917	02-10-1985			
	A67	WO 01/32217 A2	05-10-2001	Depomed, Inc.		
	A68	WO 02/060384 A2	08-08-2002	Smithkline Beecham PLC.		
	A69	WO 02/060385 A2	08-08-2002	Smithkline Beecham PLC.		
	A70	WO 02/07710 A2	01-31-2002	NW Encap Limited		
	A71	WO 02/11544 A1	02-14-2002	Encapsulation Systems, Inc.		
	A72	WO 85/00015	01-03-1985	Pharmacia AB		
	A73	WO 89/03219	04-20-1989	BORODY, Thomas, Julius		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, enter the year and month of filing. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a checkmark here if filing under the Transnational Patent System (TNPS). This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: June 13, 2007

(use as many sheets as necessary)

Sheet

4

of

5

Complete If Known

Application Number	10/604,576
Filing Date	03/19/2004
First Named Inventor	Fred H. MILLER
Art Unit	1609
Examiner Name	Aradhana Sasan

Attorney Docket Number 027668-0108

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² "Number" ³ Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	A74	WO 90/11129	10-04-1990	Nehézvegyipari Kutato Intézet		
	A75	WO 92/11848	07-23-1992	The Procter & Gamble Company		
	A76	WO 93/00439	01-07-1993	Brown University Research Foundation		
	A77	WO 94/23770	10-27-1994	Leiras OY		
	A78	WO 95/10262	04-20-1995	R.P. Scherer Corporation		
	A79	WO 96/02236	02-01-1996	MOORE, Trevor		
	A80	WO 96/10996	04-18-1996	The University of Kentucky Research Foundation		
	A81	WO 99/30693	06-24-1999	Axcan Pharma Inc.		
	A82	WO 99/59413	11-25-1999	Shanghai Sine Pharmaceutical Corp., LTD.		
	A83	WO 95/16438	06-22-1995	Cortects Limited		
	A84	WO 92/06680	04-30-1992	Cortects Limited		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A85	"Pfizer: Caduet approved in US The FDA has approved Pfizer's Caduet in the US," DATAMONITOR COMMENTWIRE, February 4, 2004, 1 PG.	
	A86	"The Hard Gelatin Capsule Advantage," Innercap Technologies Inc., 2004, pp. 2-9.	
	A87	Michael HOPKIN, "A healthy heart in a single pill," Nature News Service, Macmillan Magazines Ltd, June 27, 2003, pp. 1 & 2.	
	A88	Alexis BORISY, et al., "Systematic discovery of multicomponent therapeutics," PNAS, Vol. 100, No. 9, June 24, 2003, pp. 7977-7982.	
	A89	Drug Delivery Technology, 2005, vol. 5, no. 9, pp. 40-86.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 3 Enter reference that is not a document by the applicant. 4 Enter reference that is not a document by the applicant. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WASH_1890805.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Date Submitted: June 13, 2007

(use as many sheets as necessary)

Sheet

5

of

5

Complete If Known

Application Number	10/804,576
Filing Date	03/19/2004
First Named Inventor	Fred H. MILLER
Art Unit	1609
Examiner Name	Aradhana Sasan
Attorney Docket Number	027668-0108

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A90	"Geminex – Dual Drugs, Dual Releases," Drug Delivery Technologies – Geminex – Penwest Pharmaceutical Co., 2003, 1 pg	
	A91	"Layer Capsules ENCAP DRUG DELIVERY," layer capsules co-administer solid liquid components, 2003, 1 PG.	
	A92	"Main Benefits of Liquid Fill ENCAP DRUG DELIVERY" liquid fill encapsulation beats tablet alternative, http://www.encapdrugdelivery.com/benefits.html , 2003, 1 PG.	
	A93	"DuoCap Capsules™, ENCAP DRUG DELIVERY" liquid fill encapsulation preferable to tablet alternative, http://www.encapdrugdelivery.com/multi-component.html , 2003. PGS. 1 & 2.	
	A94	"What does encap do?, ENCAP DRUG DELIVERY" pharmaceutical companies prefer liquid fill capsule solutions, http://www.encapdrugdelivery.com/ , 2003, 1 PG.	
	A95	"Ingestible Encapsulation," BioProgress I Ingestible Encapsulation, http://www.bioprogress.com/ingestible.html , 2003 pp. 1-2.	
	A96	Scott HENSLEY, "Drug Makers 'Combos' Treat Two Disorders With One Pill," The Wall Street Journal, 2004, (Copyright © 2004, Dow Jones & Company, Inc.), pp. 1-3.	
	A97	"FDA Approves Pfizer Medicine Caduet for the Treatment of Hypertension and High Cholesterol," FDA Approves Pfizer Medicine Caduet for the Treatment of Hypertension and High Cholesterol, http://www.medicalnewstoday.com/medicalnews.php?newsid=5666 , February 3, 2004, pp. 1-3.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds of USPTO Patent Documents at www.uspto.gov. 3 Serial number or docket number of the application or docket number of the related application. 4 Serial number of the document. An indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WASH_1890805.1